Welcome to our dedicated page for Lixte Biotechnology Hldgs news (Ticker: LIXT), a resource for investors and traders seeking the latest updates and insights on Lixte Biotechnology Hldgs stock.
Lixte Biotechnology Holdings, Inc. reports clinical-stage oncology developments centered on LB-100, its proprietary first-in-class PP2A inhibitor. Recurring updates describe proof-of-concept work in ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma, including combination studies with immunotherapy and other cancer-treatment approaches.
The company also issues news on its broader cancer-treatment platform, including Liora Technologies Europe, radiotherapy technology, patent coverage, trial-site and collaborator activity, capital raises, annual-report highlights, executive and board changes, and investor-conference participation. Its public updates frame LIXT as a clinical-stage pharmaceutical and med-tech issuer focused on new targets for cancer drug development.
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) has announced an agreement to conduct a Phase 1b clinical trial with City of Hope, focusing on the combination of its protein phosphatase inhibitor, LB-100, with a standard chemotherapy regimen for extensive stage disease small cell lung cancer (ED-SCLC). The trial aims to assess LB-100’s safety and therapeutic activity when combined with carboplatin, etoposide, and atezolizumab. LB-100 has shown promise in animal models by enhancing chemotherapy's antitumor effects without added toxicity.
On December 1, 2020, WallachBeth Capital announced the completion of a joint underwritten public offering for Lixte Biotechnology Holdings, Inc. (LIXT). The offering involved 1,200,000 shares priced at $4.75 each, generating gross proceeds of $5.7 million. Each unit comprises one share of common stock and one warrant with an exercise price of $5.70. The option for underwriters to purchase an additional 180,000 shares exists. Trading for these securities commenced on November 25, 2020, and this offering is filed under an effective SEC registration statement.
Lixte Biotechnology Holdings has completed a public offering of 1,200,000 units at a price of $4.75 per unit, totaling $5.7 million in gross proceeds. Each unit comprises one share of common stock and one warrant at an exercise price of $5.70. The offering, which closed on December 1, 2020, included an option for underwriters to purchase an additional 180,000 shares and/or warrants.
The securities began trading separately on the Nasdaq Capital Market on November 25, 2020.
Lixte Biotechnology Holdings, Inc. has successfully closed a follow-on offering, selling 1,200,000 units at $5,700,000 in total gross proceeds. Each unit comprises one share of common stock and one warrant. The offering, managed by WestPark Capital, Inc., is part of an effective registration statement filed with the SEC. The company, trading on Nasdaq under the symbols LIXT and LIXTW, focuses on innovative drug discovery targeting enzyme-related diseases, with a pipeline aimed at both cancer and other serious health conditions.
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) announced a public offering of 1,200,000 units priced at $4.75 per unit, each consisting of one share of common stock and one warrant. The warrants are exercisable at $5.70, expiring in five years. The offering, following a reverse stock split of 1-for-6, aims to raise approximately $5.7 million for clinical trials, patent extensions, and general corporate purposes. The offering is expected to close around November 30, 2020, with underwriters granted an option for an additional 180,000 shares or warrants.